Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

Trial Profile

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Antipsoriatics
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms Complete-PS
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 14 Mar 2022 Results compare real-world effectiveness of adalimumab versus topical/traditional systemic agents for management of moderate to severe plaque psoriasis, published in the Dermatology and Therapy
    • 11 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top